Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a research report sent to investors on Tuesday morning,RTT News reports. Wedbush currently has a $48.00 price target on the stock.

A number of other brokerages have also recently commented on KNSA. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Citigroup increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. The Goldman Sachs Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Finally, Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Trading Up 1.0%

NASDAQ KNSA opened at $40.99 on Tuesday. The company has a market cap of $3.11 billion, a price-to-earnings ratio of 91.09 and a beta of 0.02. The company has a 50 day moving average of $39.46 and a 200-day moving average of $33.82. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $42.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s revenue was up 61.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.18) EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 42,000 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $38.33, for a total transaction of $1,609,860.00. Following the completion of the transaction, the chief operating officer directly owned 34,552 shares in the company, valued at approximately $1,324,378.16. This represents a 54.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael R. Megna sold 50,490 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $38.87, for a total value of $1,962,546.30. Following the completion of the transaction, the chief accounting officer owned 27,046 shares of the company’s stock, valued at $1,051,278.02. The trade was a 65.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 494,439 shares of company stock worth $19,066,573 over the last 90 days. 53.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently bought and sold shares of KNSA. EverSource Wealth Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Corebridge Financial Inc. raised its holdings in Kiniksa Pharmaceuticals International by 3.6% in the 1st quarter. Corebridge Financial Inc. now owns 15,979 shares of the company’s stock valued at $355,000 after buying an additional 549 shares during the last quarter. Martingale Asset Management L P boosted its position in Kiniksa Pharmaceuticals International by 1.3% during the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company’s stock worth $1,111,000 after buying an additional 640 shares during the period. Mariner LLC boosted its position in Kiniksa Pharmaceuticals International by 5.8% during the 3rd quarter. Mariner LLC now owns 13,253 shares of the company’s stock worth $515,000 after buying an additional 732 shares during the period. Finally, USA Financial Formulas bought a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $32,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.